Analytical Data
-
Gene name
PCSK9
-
简介
The PCSK9 protein regulates cholesterol levels by degrading LDLR, VLDLR, LRP1/APOER, and LRP8/APOER2 receptors. It promotes LDLR degradation, inhibits recycling, induces ubiquitination, and affects APOB degradation. Additionally, PCSK9 influences BACE1 intermediates, ENaC surface expression, and neuronal apoptosis by modulating LRP8/APOER2 levels and anti-apoptotic signaling pathways. PCSK9 Protein, Mouse (HEK293, His, solution) is the recombinant mouse-derived PCSK9 protein, expressed by HEK293, with C-6*His labeled tag.
- Application
-
Biological Activity
Measured by its binding ability in a functional ELISA. When Recombinant Mouse LDLR Protein is immobilized at 2 µg/mL (100 µL/well) can bind Mouse PCSK9 Protein. The ED50 for this effect is 145.3ng/mL. Measured by its binding ability in a functional ELISA. When Recombinant Mouse LDLR Protein is immobilized at 2 µg/mL (100 µL/well) can bind Mouse PCSK9 Protein. The ED50 for this effect is 145.3 ng/mL.
-
Alternative Names
Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; Pcsk9; Narc1
-
Species
Mouse
-
Source
HEK293
-
Tag
C-6*His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q80W65
-
Expression Region
Q80W65 (Q35-Q155&S156-Q694)
-
AA Sequence
QDEDGDYEELMLALPSQEDGLADEAAHVATATFRRCSKEAWRLPGTYIVVLMEETQRLQIEQTAHRLQTRAARRGYVIKVLHIFYDLFPGFLVKMSSDLLGLALKLPHVEYIEEDSFVFAQSIPWNLERIIPAWHQTEEDRSPDGSSQVEVYLLDTSIQGAHREIEGRVTITDFNSVPEEDGTRFHRQASKCDSHGTHLAGVVSGRDAGVAKGTSLHSLRVLNCQGKGTVSGTLIGLEFIRKSQLIQPSGPLVVLLPLAGGYSRILNAACRHLARTGVVLVAAAGNFRDDACLYSPASAPEVITVGATNAQDQPVTLGTLGTNFGRCVDLFAPGKDIIGASSDCSTCFMSQSGTSQAAAHVAGIVARMLSREPTLTLAELRQRLIHFSTKDVINMAWFPEDQQVLTPNLVATLPPSTHETGGQLLCRTVWSAHSGPTRTATATARCAPEEELLSCSSFSRSGRRRGDWIEAIGGQQVCKALNAFGGEGVYAVARCCLVPRANCSIHNTPAARAGLETHVHCHQKDHVLTGCSFHWEVEDLSVRRQPALRSRRQPGQCVGHQAASVYASCCHAPGLECKIKEHGISGPSEQVTVACEAGWTLTGCNVLPGASLTLGAYSVDNLCVARVHDTARADRTSGEATVAAAICCRSRPSAKASWVQ
-
Protein Length
Full Length of Mature Protein (with Propeptide)
-
Molecular Weight
17-19 & 60-66 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) is a key regulator of cholesterol metabolism, primarily by modulating the levels of low-density lipoprotein (LDL) receptors on the surface of hepatocytes. Elevated levels of PCSK9 result in reduced LDL receptor availability, leading to increased LDL cholesterol levels in the bloodstream, which is a major risk factor for cardiovascular diseases. Research into PCSK9 has gained momentum due to the discovery of genetic mutations that either increase or decrease its activity, providing insights into its role in lipid metabolism. The development of PCSK9 inhibitors represents a promising therapeutic strategy for managing hypercholesterolemia and reducing cardiovascular risks, especially in patients who are resistant to conventional lipid-lowering therapies. Recombinant PCSK9 proteins have been utilized in various experimental setups to better understand its function and interactions within cholesterol homeostasis. These studies aim to elucidate the molecular mechanisms by which PCSK9 affects LDL receptor processing and recycling, contributing to the design of targeted treatments that disrupt the PCSK9-LDL receptor interaction. As a result, the field of cardiovascular research is increasingly focused on elucidating the complex pathways involving PCSK9, with the ultimate goal of translating these findings into effective clinical interventions that lower cholesterol levels and improve patient outcomes. In summary, the study of recombinant PCSK9 proteins is pivotal in advancing our understanding of cholesterol regulation and the potential for innovative therapies in the fight against cardiovascular diseases.
